Chong Kun Dang targets foreign tourists with skin disease medicines
Predicted impact: Low
Same foreign-tourist skin medicine push; the K-Pharmacy recommendation was already reported in the last 14 days.
Chong Kun Dang Pharmaceutical종근당
185750 · KOSPI · ₩185750 · 종근당
₩61,900▲ ₩600 (0.98%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −25.69%
STOP ₩65,300DCA3 ₩64,300DCA2 ₩63,300DCA1 ₩62,300Entry ₩61,300TP1 ₩59,300TP2 ₩57,300TP3 ₩54,400TP4 ₩51,400TP5 ₩45,400
Entry, trailing stop, targets and DCA levels of the current Squeeze! setup (paper-trading levels from a fixed rule, not advice).
- Market cap
- ₩854B
- Enterprise value
- ₩996B
- P/E
- 10.8×
- P/B
- 0.8×
- Dividend yield
- 0.8%
- ROE
- 7.8%
- Net margin
- 4.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−36.9% from the high
₩61,000Today: ₩61,400 – ₩62,800₩98,100
Returns
- 1W−6.8%
- 1M−5.4%
- 3M−5.6%
- 6M−28.8%
- YTD−25.3%
- 1Y−25.7%
- Volume today
- 11,498
- 0.6× the 20-day average
- Traded today
- ₩716M
- Listed shares
- 13,802,780
- EPS (12 months)
- ₩5,758
- Earnings yield 9.3%
AI research · Update noteChong Kun Dang: Model Fair Value Estimate Rises to ₩88,607 per Share from ₩36,731The evidence is mixed and the change is mainly about the model, not the company.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 35 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Coverage focuses on tourism marketing and an award, with no financial or regulatory news. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-4.6% over the last month; the price is below its 20-day average.
- News impactLow11 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Futures and options
All stock futures →Futures (2026-11): 61,400
Basis −0.81% · implied rate −19.7%
Open interest 1,114 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Chong Kun Dang Pharmaceutical stock overview
Chong Kun Dang Pharmaceutical (종근당, KRX: 185750) is listed on KOSPI, in the Biotech & Pharma sector. Jong-keun Dang (Chong Kun Dang) is one of South Korea's large pharmaceutical companies, founded in 1941 as Gungbon Pharmacy and listed on the Korea Exchange since 1976. Its shares closed at ₩61,900 on Oct 28, 2026, up 0.98% on the day, giving it a market value of ₩854B.
Key facts
- Market cap
- ₩854B
- Sector
- Biotech & Pharma
- Latest price change
- +0.98%
- As of
- Oct 28, 2026
- Main business
- Jong-keun Dang (Chong Kun Dang) is one of South Korea's large pharmaceutical companies, founded in 1941 as Gungbon Pharmacy and listed on the Korea Exchange since 1976.
Quick answers about Chong Kun Dang Pharmaceutical
- What does Chong Kun Dang Pharmaceutical do?
- Jong-keun Dang (Chong Kun Dang) is one of South Korea's large pharmaceutical companies, founded in 1941 as Gungbon Pharmacy and listed on the Korea Exchange since 1976. The company develops, manufactures and sells prescription drugs (ETC) and over-the-counter drugs (OTC), with a product lineup spanning areas such as osteoporosis, lipid-lowering, diabetes, hypertension, transplant immunosuppressants and cerebrovascular disease treatments. It invests in new drug, improved-drug and generic development, and its products are sold in the Korean pharmaceutical market.
- What is the market cap of Chong Kun Dang Pharmaceutical?
- The market capitalisation of Chong Kun Dang Pharmaceutical was ₩854B at the close on Oct 28, 2026.
- Who are the largest shareholders of Chong Kun Dang Pharmaceutical?
- According to the latest official filings, the largest reported holders are Chong Kun Dang Holdings (40.15%, as of Oct 8, 2026); KopernikGlobalInvestors,LLC (8.38%, as of Jun 26, 2026); National Pension Service (6.34%, as of Jul 1, 2026).
- When is the next earnings report from Chong Kun Dang Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Chong Kun Dang Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Chong Kun Dang Pharmaceutical?
- Yes. The National Pension Service held 6.34% of Chong Kun Dang Pharmaceutical shares as of Jul 1, 2026.
Company profile
Jong-keun Dang (Chong Kun Dang) is one of South Korea's large pharmaceutical companies, founded in 1941 as Gungbon Pharmacy and listed on the Korea Exchange since 1976. The company develops, manufactures and sells prescription drugs (ETC) and over-the-counter drugs (OTC), with a product lineup spanning areas such as osteoporosis, lipid-lowering, diabetes, hypertension, transplant immunosuppressants and cerebrovascular disease treatments. It invests in new drug, improved-drug and generic development, and its products are sold in the Korean pharmaceutical market.
Written by AI from the company's latest annual report.
- Korean name
- 종근당
- Sector
- Biotech & Pharma
- CEO
- 김영주
- Founded
- Nov 2013
- Listed
- Dec 2013
- Listed shares
- 13,802,780
- Fiscal year ends
- Month 12
- Website
- www.ckdpharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Chong Kun Dang pharmaceutical targets Japan-bound visitors with skin medicine
Predicted impact: Low
Skin medicine marketing to tourists; the K-Pharmacy recommendation was already reported in the last 14 days.
Chong Kun Dang Pharmaceutical's Aimvita wins food category grand prize at the 2026 Korea SNS Awards
Predicted impact: Low
Consumer product award; marketing recognition with no financial size.
Recent filings
See all- Amended: Half-year report (Jun 2026)Oct 22, 2026
- Amended: Half-year report (Jun 2026)Oct 22, 2026
- Amended: Half-year report (Jun 2026)Oct 22, 2026
- Change in largest shareholder's holdingsOct 8, 2026
- 5%+ holding reportOct 8, 2026
Titles in Korean until English translations are added.
Also known as: Chong Kun Dang Pharmaceutical / 종근당 / 185750 / KRX:185750
Source: KRX statistical information